Intratumoral delivery of crystallized IDO1 inhibitor IDO5L does not improve tumor control in murine tumor models
The tryptophan (Trp)-degrading enzyme indoleamine 2,3-dioxygenase 1 (IDO1) contributes to immunoregulatory pathways in the tumor microenvironment, yet clinical development of IDO1 inhibitors has yielded limited efficacy. We investigated whether intratumoral (IT) administration of a precipitated, crystal-like formulation of the IDO1 inhibitor IDO5L could improve tumor control compared with soluble IDO5L delivered subcutaneously (SC) or intravenously (IV). The formulation was prepared by antisolvent precipitation and examined by light microscopy. Antitumor effects were evaluated in murine 4T1 mammary carcinoma and B16F10 fragment-transplantation models, with exploratory endpoint metabolomics performed in 4T1 tumors. None of the tested IDO5L regimens produced a detectable improvement in tumor control. Measured tumor-infiltrating immune-cell densities did not differ significantly between the examined treatment groups, although immune-cell function was not assessed. LC-MS profiling revealed treatment-associated variation in metabolite signals and higher mean nicotinamide riboside abundance in IT-treated 4T1 tumors; these findings do not establish activation of the NAD + salvage pathway or a causal mechanism of resistance. Complementary administration of Trp, including by the IT route, also did not improve tumor control in 4T1. Together, these results document the feasibility of administering precipitated IDO5L directly into tumors and the absence of a detected antitumor benefit under the tested conditions. Because intratumoral drug exposure, IDO1 target engagement, and release kinetics were not measured, the experiments do not establish whether effective IDO1 inhibition was achieved.
Institutions
- University of Bern (CH)
- University Hospital of Bern (CH)
Publication Details
- Journal
- Biochemistry and Biophysics Reports
- Published
- 2026-11-17
- DOI
- https://doi.org/10.1016/j.bbrep.2026.102866
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
- Swiss Cancer Research Foundation